Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for therapeutic response are under intensive investigation, aiming at a tailored patient management and more appropriate resource utilization. This review summarizes the available data on the tissue, circulating and imaging markers that are potentially predictive of rapalog efficacy in NETs.

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours / Zatelli, Maria Chiara; Fanciulli, Giuseppe; Malandrino, Pasqualino; Ramundo, Valeria; Faggiano, Antongiulio; Colao, Annamaria. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - 23:3(2016), pp. R173-R183. [10.1530/ERC-15-0413]

Predictive factors of response to mTOR inhibitors in neuroendocrine tumours

Ramundo, Valeria
Writing – Original Draft Preparation
;
Faggiano, Antongiulio;
2016

Abstract

Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for therapeutic response are under intensive investigation, aiming at a tailored patient management and more appropriate resource utilization. This review summarizes the available data on the tissue, circulating and imaging markers that are potentially predictive of rapalog efficacy in NETs.
2016
mTOR inhibitors; neuroendocrine tumours; predictors; response to treatment; animals; antineoplastic agents; biomarkers, tumor; diagnostic imaging; humans; neuroendocrine tumors; Protein Kinase Inhibitors; TOR Serine-Threonine Kinases
01 Pubblicazione su rivista::01a Articolo in rivista
Predictive factors of response to mTOR inhibitors in neuroendocrine tumours / Zatelli, Maria Chiara; Fanciulli, Giuseppe; Malandrino, Pasqualino; Ramundo, Valeria; Faggiano, Antongiulio; Colao, Annamaria. - In: ENDOCRINE-RELATED CANCER. - ISSN 1351-0088. - 23:3(2016), pp. R173-R183. [10.1530/ERC-15-0413]
File allegati a questo prodotto
File Dimensione Formato  
Faggiano_Neuroendocrine-tumors.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 215.08 kB
Formato Adobe PDF
215.08 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1120838
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 26
social impact